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The dose of quinidine in the studies quoted above was 10
mg/kg body weight orally every 8 hours for 7 days. Unfortunately,
no parenteral formulation of quinidine is available in South Africa,
and in the appropriate patient administration via a nasogastric
tube may be suitable.
It must be emphasised that the above suggestions should not
delay the attending physician from transferring the patient to an
appropriate treatment centre or from obtaining quinine as soon as
possible.
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The cnear-balanced diet' for
ulcerative colitis
To the Editor: Dr J. P. Wrighrs comments on my letter l have
been noted, and I reply as follows:
The chapter2 quoted by Dr Wright is headed 'The effects of
malnutrition on the immune responses'. But it deals largely with
the effects of shortages of single components of food on the
immune status, shortages that are unlikely to occur in the presence
of balanced nutrition.
Evidence has been providedl that antibodies to Escherichia coli
have been found in the serum of ulcerative colitis patients. This
suggests that these organisms have breached the debilitated
intestinal wall, presumably through the ulcerated areas, and gained
access to the bloodstream. Can there be any clearer understanding
of the causation and underlying pathophysiology than this?
The concept of the absence of some protective mechanism that
normally inhibits the bacterial invasion of the intestinal wall is not
new. 4,5 However, to the best of my knowledge, the method I
suggested (the 'near-balanced dier l ) of restoring the protective
mechanism is original. The 'near-balanced diet' that I recommend
has been developed experimentally over a period of 26 years with
the specific aim of enhancing immunocompetence. Numerous
papers have been written, of which 6 have been published. It is
therefore incorrect to refer to my work as 'anecdotal experiences',
and unfair to compare the 'near-balanced dier with 'hunch diets'
that have been tried.6,7
Acquired lactose intolerance may be related to indifferent health
and might subside if health (e.g. liver function) was upgraded by
improving nutrition. Unadulterated full-cream milk (almost un-
obtainable in the USA and Canada) taken at mealtimes increases
the variety of foodstuffs consumed, thus improving the balance of
the nutrition.
The last paragraph of Dr Wright's comments carries a suggestion
of contradiction in that he admits that conventional methods of
treatment are not infrequently unsuccessful but goes on to claim
that the 'few proven therapeutic options' offer the best chance of
recovery. Here I point out that because, as seems likely, ulcerative
colitis is a disease involving impaired immunocompetence, it is
quite wrong to use drugs such as corticosteroids, which have the





1. Bailey N. The 'near-balanced diet' for ulcerative colitis (Lener). S Afr Med
J 1990; 78: 221-222.
2. Myrvik QN. Nutrition and inlmunology. In: Shils ME, Young YR, 005.
Modern Nurrition in Health and Disease. 7th 00. Pbiladelphia: Lea & Febiger,
1988.
3. Perlmann P, Hammarstrom S, Lagercrantz S, Campbell D. Auto-antibodies
to colon in rats and human ulcerative colitis: cross reactivity and Escherichia
coli 0: 14 antigen. Proc Soc Erp Bioi Med 1967; 125: 975-980.
4. Logan AH. Chronic ulcerative colitis: a review of 117 cases. NOTthmesr Med
1919; 18: 1-9.
5. Brown TR. Some observations on chronic ulcerative colitis. Ann Clin Med
1925; 4: 425-429. ..
6. Jones VA, Dickenson RJ, Workman E er al. Crohn's disease: maintenance of
remission by diet. LlJ1lCer1985; 2: 177-178. .
7. Heaton KW, Thomton JR, Emmen PM. Treatment of Crohn's disease with
an unrefinOO-earbohydrate, fibre-rich diet. Br MedJ 1979; 2: 764-765,
Erratum
In the article 'Quantifying non-eompliance in patients receiving
digoxin - a pharmacokinetic approach' by Wiseman and Miller,
which appeared on pp. 155 - 157 of the SAM] pf 2 February, the
following printing errors occurred.
On p. 155 the equation used to calculate the predicted average
plasma concentration of digoxin at steady state for each patient
should have appeared as follows: .
DXFX 106
Cpss nglml = CI
B
ml/min X T
On p. 56, under 'Results', the 6th line down should have read:
, .. which was 61,6% greater than the mean serum concentra-
tion .. .', while the 20th line should have read: '... which was
151~4% greater rhan the meap. serum concentration .. .'.
We apologise to the authors and readers for these errors.
